Icu Medical Stock Earnings Reports

ICU Medical reported Q1 FY2026 revenue of $526 million, up 1% organically but down 12% reported due to the mid-2025 deconsolidation of IV Solutions (Otsuka JV). Adjusted gross margin improved to ~41% driven by mix and integration synergies. Adjusted EBITDA was $99 million and adjusted EPS was $1.97. Free cash flow was $28 million and net leverage was largely unchanged. Business highlights: Consumables grew modestly (5% reported / 2% organic) with ongoing 510(k) activity and two new clearances in Q1; Infusion Systems posted record pump revenue (8% reported / 6% organic) and the company prioritized Medfusion hardware testing before CADD; Vital Care continued to decline organically (‑14%) and management is exiting noncore SKUs (example: a shrinking Japanese surgical commodities line). Regulatory/FDA update: FDA is requesting larger-sample testing for new pump hardware which will lengthen timing but does not reflect core technology issues. Macro and cost dynamics: tariffs and elevated diesel/logistics costs are material variables — management estimates ~ $10 million incremental logistics expense for 2026 under current oil/diesel forecasts, largely offset by slightly lower temporary tariffs and accelerated operational efficiencies. Guidance: management reaffirmed prior full-year guidance and expects the puts-and-takes (tariffs, logistics, efficiencies) to largely offset. Capital allocation / strategy: focus on completing integration projects, driving margins (targeting ~2 more percentage points of improvement), returning to ≤2x leverage over time, and prioritizing organic innovation; M&A needs are limited. Overall tone: cautious but confident — core businesses are growing, near‑term integration spending is peaking/declining, regulatory timing for pump hardware is incremental but manageable, and management expects to deliver on long‑term goals while navigating macro volatility.